FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Lein

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Prostate

Procedures

Activities & Behaviors

Neural Networks (Computer)

Co-author Network

Publications

TOP 3
Jonas Busch; Stefan Hinz; Carsten Kempkensteffen; Ergin Kilic; Annett Klutzny; Michael Lein; Kurt Miller; Carsten Stephan; Steffen Weikert; Ahmed Magheli
Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results.
Juan R Rodrigues; Arthur Barazarte; José Camacho; Jaime Charris; Neira Gamboa; Michael Höpfner; Klaus Jung; Michael Lein; Bianca Nitzsche; Claudia Abramjuk
N'-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies.
Jonas Busch; Kristin Hamborg; Klaus Jung; Michael Lein; Ahmed Magheli; Hellmuth-Alexander Meyer; Kurt Miller; John Buckendahl; Carsten Stephan
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Lein (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jonas Busch; Stefan Hinz; Carsten Kempkensteffen; Ergin Kilic; Annett Klutzny; Michael Lein; Kurt Miller; Carsten Stephan; Steffen Weikert; Ahmed Magheli
Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results.
World journal of urology 2013;31(2):395-401.
2013: Juan R Rodrigues; Arthur Barazarte; José Camacho; Jaime Charris; Neira Gamboa; Michael Höpfner; Klaus Jung; Michael Lein; Bianca Nitzsche; Claudia Abramjuk
N'-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies.
The Journal of pharmacy and pharmacology 2013;65(3):411-22.
2012: Jonas Busch; Kristin Hamborg; Klaus Jung; Michael Lein; Ahmed Magheli; Hellmuth-Alexander Meyer; Kurt Miller; John Buckendahl; Carsten Stephan
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis.
The Journal of urology 2012;188(6):2165-70.
2012: Jonas Busch; Barbara Erber; Anja Herold; Stefan Hinz; Carsten Kempkensteffen; Michael Lein; Kurt Miller; Carsten Stephan; Steffen Weikert; Ahmed Magheli
Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience.
BJU international 2012;110(11 Pt C):E985-90.
2012: Juan R Rodrigues; Jorge Angel; Jaime Charris; Rosa Ferrer; Neira Gamboa; Michael Hoepfner; Klaus Jung; Michael Lein; Bianca Nitzsche; Claudia Abramjuk
Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo.
Investigational new drugs 2012;30(4):1426-33.
2011: Ahmed Magheli; Stefan Hinz; Carsten Kempkensteffen; Nina Knoll; Michael Lein; Oliver Gralla
Impact of fast-track postoperative care on intestinal function, pain, and length of hospital stay after laparoscopic radical prostatectomy.
Journal of endourology / Endourological Society 2011;25(7):1143-7.
2011: Carsten Stephan; Kurt Miller; Mark Schrader; Kerstin Siemssen; Henning Cammann; Serdar Deger; Frank Friedersdorff; Klaus Jung; Michael Lein; Hellmuth-Alexander Meyer
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms.
Clinical chemistry 2011;57(7):995-1004.
2011: Klaus Jung; Kurt Miller; Manfred Wirth; Michael Albrecht; Michael Lein
Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid.
European urology 2011;59(4):604-12.
2011: Juan Rodrigues; Claudia Abramjuk; Luis Vásquez; Neira Gamboa; José Domínguez; Bianca Nitzsche; Michael Höpfner; Radostina Georgieva; Hans Bäumler; Carsten Stephan; Klaus Jung; Michael Lein; Anja Rabien
New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.
Pharmaceutical research 2011;28(4):907-19.
2011: Florian Jentzmik; Carsten Stephan; Michael Lein; Kurt Miller; Beate Kamlage; Bianca Bethan; Glen Kristiansen; Klaus Jung
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
The Journal of urology 2011;185(2):706-11.
2010: Annika Schaefer; Monika Jung; Kurt Miller; Michael Lein; Glen Kristiansen; Andreas Erbersdobler; Klaus Jung
Suitable reference genes for relative quantification of miRNA expression in prostate cancer.
Experimental & molecular medicine 2010;42(11):749-58.
2010: Florian Jentzmik; Martin Schostak; Carsten Stephan; Daniel Baumunk; Anja Lingnau; Steffen Weikert; Michael Lein; Kurt Miller; Mark Schrader
Extraperitoneal radical cystectomy with extraperitonealization of the ileal neobladder: a comparison to the transperitoneal technique.
World journal of urology 2010;28(4):457-63.
2010: Florian Jentzmik; Carsten Stephan; Kurt Miller; Mark Schrader; Andreas Erbersdobler; Glen Kristiansen; Michael Lein; Klaus Jung
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.
European urology 2010;58(1):12-8; discussion 20-1.
2010: B Nitzsche; C Gloesenkamp; Mark Schrader; M Ocker; R Preissner; Michael Lein; Andreas Zakrzewicz; B Hoffmann; Michael Höpfner
Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.
British journal of cancer 2010;103(1):18-28.
2010: Isabel Steiner; Klaus Jung; Philipp Schatz; Torsten Horns; Daniel Wittschieber; Michael Lein; Manfred Dietel; Andreas Erbersdobler
Gene promoter methylation and its potential relevance in early prostate cancer diagnosis.
Pathobiology : journal of immunopathology, molecular and cellular biology 2010;77(5):260-6.
2010: Carsten Stephan; Henning Cammann; Martin Bender; Kurt Miller; Michael Lein; Klaus Jung; Hellmuth-A Meyer
Internal validation of an artificial neural network for prostate biopsy outcome.
International journal of urology : official journal of the Japanese Urological Association 2010;17(1):62-8.
2010: Ahmed Magheli; Stefan Hinz; Claudia Hege; Carsten Stephan; Klaus Jung; Kurt Miller; Michael Lein
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
The Journal of urology 2010;183(1):126-31.
2010: J Busch; C Röllig; Lothar Weissbach; Carsten Kempkensteffen; Stefan Hinz; Cosima Jahnke; Martin Schostak; Michael Lein; Steffen Weikert; Carsten Stephan; Serdar Deger; G Ollenschläger; Kurt Miller; Mark Schrader
[What is most important is what comes across : Urological guidelines from the target group's point of view].
Der Urologe. Ausg. A 2010;49(1):75-80.
2010: Annika Schaefer; Monika Jung; Glen Kristiansen; Michael Lein; Mark Schrader; Kurt Miller; Carsten Stephan; Klaus Jung
MicroRNAs and cancer: current state and future perspectives in urologic oncology.
Urologic oncology 2010;28(1):4-13.
2009: Carsten Stephan; Henning Cammann; Serdar Deger; Mark Schrader; Hellmuth-Alexander Meyer; Kurt Miller; Michael Lein; Klaus Jung
Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Urology 2009;74(4):873-7.
2009: Claudia Abramjuk; Michael Bueschges; Jörg Schnorr; Klaus Jung; Andrea Staack; Michael Lein
Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Oncology reports 2009;22(2):409-14.
2009: Carsten Stephan; Harry Rittenhouse; Henning Cammann; Michael Lein; Mark Schrader; Serdar Deger; Kurt Miller; Klaus Jung
New markers and multivariate models for prostate cancer detection.
Anticancer research 2009;29(7):2589-600.
2009: Michael Lein; Kurt Miller; Manfred Wirth; Lothar Weissbach; Christoph May; Katja Schmidt; Ulrike Haus; Mark Schrader; Klaus Jung
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
The Prostate 2009;69(6):624-32.
2009: Carsten Stephan; Chris Bangma; Giulio Vignati; Georg Bartsch; Michael Lein; Klaus Jung; Marianne Philippe; Axel Semjonow; William J Catalona
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
The International journal of biological markers 2009;24(2):65-9.
2009: Carsten Stephan; Anna-Maria Kahrs; Henning Cammann; Michael Lein; Mark Schrader; Serdar Deger; Kurt Miller; Klaus Jung
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
The Prostate 2009;69(2):198-207.
2009: Klaus Jung; Ferdinando Mannello; Michael Lein
Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles.
Journal of translational medicine 2009;7():87.
2009: Carsten Stephan; Thomas Köpke; Axel Semjonow; Michael Lein; Serdar Deger; Mark Schrader; Kurt Miller; Klaus Jung
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(11):1325-31.
2009: Angelika Tölle; Monika Jung; Michael Lein; Manfred Johannsen; Kurt Miller; Holger Moch; Klaus Jung; Glen Kristiansen
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
BMC cancer 2009;9():248.
2009: S Deger; Michael Lein; Kurt Miller; A H Wille
[New developments in minimally invasive urology: NOTES (Natural Orifice Transluminal Endoscopic Surgery) and LESS (Laparo-Endoscopic Single-Site Surgery) in urology].
Aktuelle Urologie 2009;40(1):23-6.
2009: Mark Schrader; Carsten Kempkensteffen; Frank Christoph; Stefan Hinz; Steffen Weikert; Michael Lein; Hans Krause; Carsten Stephan; Klaus Jung; Michael Hoepfner; Peter Albers; Kurt Miller; Martin Schostak
Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options.
Oncology 2009;76(2):77-84.
2008: J Ebbing; Frank Christoph; Carsten Kempkensteffen; Steffen Weikert; Martin Schostak; Stefan Hinz; Michael Lein; Kurt Miller; Mark Schrader
[Testicular cancer - explanatory models for high cisplatin chemosensibility and new therapeutic options].
Aktuelle Urologie 2008;39(6):429-35.
2008: Klaus Jung; Azizbek Ramankulov; Mark Schrader; Kurt Miller; Michael Lein
Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma?
Clinical chemistry 2008;54(11):1927-9.
2008: Kurt Miller; Michael Lein; Martin Schostak; Mark Schrader
[Adjuvant and neoadjuvant drug therapy for prostate cancer].
Der Urologe. Ausg. A 2008;47(11):1460-4.
2008: Florian R Fritzsche; Monika Jung; Angelika Tölle; Peter Wild; Arndt Hartmann; Kirsten Wassermann; Anja Rabien; Michael Lein; Manfred Dietel; Christian Pilarsky; Daniela Calvano; Robert Grützmann; Klaus Jung; Glen Kristiansen
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
European urology 2008;54(5):1097-106.
2008: Carsten Stephan; Klaus Jung; Michael Lein; Serdar Deger
Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007).
Urology 2008;72(4):951.
2008: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Stefan A Loening; Klaus Jung
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Cancer letters 2008;269(1):85-92.
2008: Carsten Stephan; Henning Cammann; Hellmuth-Alexander Meyer; Christian Müller; Serdar Deger; Michael Lein; Klaus Jung
An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
BJU international 2008;102(7):799-805.
2008: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Klaus Jung
Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Cancer science 2008;99(6):1188-94.
2008: Carsten Stephan; Henning Cammann; Michael Lein; Kurt Miller; Klaus Jung
Re: Application of artificial intelligence to the management of urological cancer. M. F. Abbod, J. W. Catto, D. A. Linkens and F. C. Hamdy J Urol 2007; 178: 1150-1156.
The Journal of urology 2008;179(5):2067.
2008: Carsten Stephan; Anna-Maria Kahrs; Silke Klotzek; Janett Reiche; Christian Müller; Michael Lein; Serdar Deger; Kurt Miller; Klaus Jung
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):623-9.
2008: Carsten Stephan; Nicola Büker; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung
Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity.
BMC urology 2008;8():10.
2007: Kasra Taymoorian; Anke Thomas; Torsten Slowinski; Masoud Khiabanchian; Carsten Stephan; Michael Lein; Serdar Deger; Severin Lenk; Stefan A Loening; Thomas Fischer
Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies.
Anticancer research 2007;27(6C):4315-20.
2007: Michael Lein; Manfred Wirth; Kurt Miller; Hans-Udo Eickenberg; Lothar Weissbach; Katja Schmidt; Ulrike Haus; Carsten Stephan; Sven Meissner; Stefan A Loening; Klaus Jung
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
European urology 2007;52(5):1381-7.
2007: Carsten Stephan; Klaus Jung; Michael Lein; Eleftherios P Diamandis
PSA and other tissue kallikreins for prostate cancer detection.
European journal of cancer (Oxford, England : 1990) 2007;43(13):1918-26.
2007: Carsten Stephan; Chuanliang Xu; Patrik Finne; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung; Ulf-Hakan Stenman
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations.
Urology 2007;70(3):596-601.
2007: Carsten Stephan; Klaus Jung; Henning Cammann; J Kramer; Glen Kristiansen; Stefan A Loening; Michael Lein
[New serum markers in prostate carcinoma and their application to artificial neural networks].
Der Urologe. Ausg. A 2007;46(9):1084-6.
2007: Michael Lein; Azizbek Ramankulov; Carsten Stephan; J Kramer; Stefan A Loening; Klaus Jung
[New serum markers of bone metastasis in prostate carcinoma].
Der Urologe. Ausg. A 2007;46(9):1087-8.
2007: Stefan Ludwig; Carsten Stephan; Michael Lein; Stefan A Loening; Klaus Jung
S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study.
The Prostate 2007;67(12):1301-7.
2007: Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-Alexander Meyer; Stefan A Loening; Klaus Jung
Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.
Journal of cancer research and clinical oncology 2007;133(9):643-52.
2007: Carsten Stephan; Hellmuth-Alexander Meyer; Eva-Maria Paul; Glen Kristiansen; Stefan A Loening; Michael Lein; Klaus Jung
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Anticancer research 2007;27(4A):1833-6.
2007: Carsten Stephan; Jürgen Kramer; Hellmuth-Alexander Meyer; Glen Kristiansen; Sabine Ziemer; Serdar Deger; Michael Lein; Stefan A Loening; Klaus Jung
Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
BJU international 2007;99(6):1427-31.
2007: Carsten Stephan; Hellmuth-Alexander Meyer; Henning Cammann; Michael Lein; Stefan A Loening; Klaus Jung
Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236-43.
European urology 2007;51(5):1446-7; author reply 1448.
2007: Carsten Stephan; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung
PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
Cancer letters 2007;249(1):18-29.
2007: Oliver Gralla; F Haas; Nina Knoll; DA Hadzidiakos; M Tullmann; A Romer; Serdar Deger; Volko Ebeling; Michael Lein; Andreas H Wille; Benno Rehberg; Stefan A Loening; Jan Roigas
Fast-track surgery in laparoscopic radical prostatectomy: basic principles.
World journal of urology 2007;25(2):185-91.
2007: Glòria Tabarés; Klaus Jung; Janett Reiche; Carsten Stephan; Michael Lein; Rosa Peracaula; Rafael de Llorens; Wolfgang Hoesel
Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples.
Clinical biochemistry 2007;40(5-6):343-50.
2007: Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Stefan A Loening; Klaus Jung
Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.
The Prostate 2007;67(3):330-40.
2007: Klaus Jung; Wolfgang Hoesel; Janett Reiche; Serdar Deger; Jürgen Kramer; Stefan A Loening; Michael Lein; Carsten Stephan
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Urology 2007;69(2):320-5.
2007: Claudia Abramjuk; Michael Lein; Winfried Rothaug; Hans-Willi Krell; Stefan A Loening; Klaus Jung
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Cancer chemotherapy and pharmacology 2007;59(2):275-82.
2007: Sabine Beutner; Matthias May; Bernd Hoschke; Christian Helke; Michael Lein; Jan Roigas; Manfred Johannsen
Treatment of varicocele with reference to age: a retrospective comparison of three minimally invasive procedures.
Surgical endoscopy 2007;21(1):61-5.
2006: Michael Lein; Inna Stibane; Ramin Mansour; Claudia Hege; Jan Roigas; Andreas H Wille; Klaus Jung; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Serdar Deger
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte.
European urology 2006;50(6):1278-82; discussion 1283-4.
2006: Carsten Stephan; Hellmuth-Alexander Meyer; Maciej Kwiatkowski; Franz Recker; Henning Cammann; Stefan A Loening; Klaus Jung; Michael Lein
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
European urology 2006;50(5):1014-20.
2006: Klaus Jung; Michael Lein; Martin Ringsdorf; Jan Roigas; Dietmar Schnorr; Stefan A Loening; Andrea Staack
Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
The Journal of urology 2006;176(4 Pt 1):1326-31.
2006: Klaus Jung; Michael Lein; Hermann Butz; Carsten Stephan; Stefan A Loening; Thomas Keller
New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics.
The Journal of urology 2006;175(4):1275-80.
2006: Matthias May; Manfred Johannsen; Sabine Beutner; Christian Helke; Kay-Patrick Braun; Michael Lein; Jan Roigas; Bernd Hoschke
Laparoscopic surgery versus antegrade scrotal sclerotherapy: Retrospective comparison of two different approaches for varicocele treatment.
European urology 2006;49(2):384-7.
2006: Matthias May; Kasra Taymoorian; Sabine Beutner; Christian Helke; Kay-Patrick Braun; Michael Lein; Jan Roigas; Bernd Hoschke
Body size and weight as predisposing factors in varicocele.
Scandinavian journal of urology and nephrology 2006;40(1):45-8.
2005: Michael Lein; Axel Semjonow; Markus Graefen; Maciej Kwiatkowski; Claudia Abramjuk; Carsten Stephan; Alexander Haese; fianceeyi chun; Dietmar Schnorr; Stefan A Loening; Klaus Jung
A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
The Journal of urology 2005;174(6):2150-3.
2005: Claudia Abramjuk; Klaus Jung; Hans-Willi Krell; Rolf Juchem; Robert Peters; Kasra Taymoorian; Andrea Staack; Carsten Stephan; Jörg Schnorr; Stefan A Loening; Michael Lein
Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats.
Anti-cancer drugs 2005;16(8):855-61.
2005: Venugopal Bhuvarahamurthy; Joerg Schroeder; Glen Kristiansen; Jan Roigas; Carsten Denkert; Manfred Johannsen; Michael Lein; Stefan A Loening; Dietmar Schnorr; Klaus Jung; Andrea Staack
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Oncology reports 2005;14(3):777-82.
2005: Carsten Stephan; Greta Stroebel; Marc Heinau; Andre Lenz; Andreas Roemer; Michael Lein; Dietmar Schnorr; Stefan A Loening; Klaus Jung
The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Cancer 2005;104(5):993-1003.
2005: Manfred Johannsen; Burghard Thiesen; Andreas Jordan; Kasra Taymoorian; Uwe Gneveckow; Norbert Waldöfner; Regina Scholz; Martin Koch; Michael Lein; Klaus Jung; Stefan A Loening
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
The Prostate 2005;64(3):283-92.
2005: Thomas Keller; Hermann Butz; Michael Lein; Maciej Kwiatkowski; Axel Semjonow; Hans-Joachim Luboldt; Peter Hammerer; Carsten Stephan; Klaus Jung
Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen.
Clinical chemistry 2005;51(3):532-9.
2005: Serdar Deger; Markus Giessing; Jan Roigas; Andreas H Wille; Michael Lein; Bernd Schönberger; S A Loening
Laparoscopic donor nephrectomy.
Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy 2005;14(2):57-61.
2004: Klaus Jung; Michael Lein; Carsten Stephan; Katharina Von Hösslin; Axel Semjonow; Pranav Sinha; Stefan A Loening; Dietmar Schnorr
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
International journal of cancer. Journal international du cancer 2004;111(5):783-91.
2004: Manfred Johannsen; Andreas Jordan; Regina Scholz; Martin Koch; Michael Lein; Serdar Deger; Jan Roigas; Klaus Jung; Stefan A Loening
Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer.
Journal of endourology / Endourological Society 2004;18(5):495-500.
2004: Klaus Jung; Carsten Stephan; Michaela Lewandowski; Silke Klotzek; Monika Jung; Glen Kristiansen; Michael Lein; Stefan A Loening; Dietmar Schnorr
Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer.
Cancer letters 2004;205(2):173-80.
2003: Klaus Jung; Carsten Stephan; Axel Semjonow; Michael Lein; Dietmar Schnorr; Stefan A Loening
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
The Journal of urology 2003;170(6 Pt 1):2302-5.
2003: Michael Lein; Maciej Kwiatkowski; Axel Semjonow; Hans-Joachim Luboldt; Peter Hammerer; Carsten Stephan; Virgilijus Klevecka; Kasra Taymoorian; Dietmar Schnorr; Franz Recker; Stefan A Loening; Klaus Jung
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.
The Journal of urology 2003;170(4 Pt 1):1175-9.
2003: Carsten Stephan; B Vogel; Henning Cammann; Michael Lein; Virgilijus Klevecka; Pranav Sinha; Glen Kristiansen; Dietmar Schnorr; Klaus Jung; Stefan A Loening
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l].
Der Urologe. Ausg. A 2003;42(9):1221-9.
2003: Sebastian Wesseling; Carsten Stephan; Axel Semjonow; Michael Lein; Brigitte Brux; Pranav Sinha; Stefan A Loening; Klaus Jung
Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Clinical chemistry 2003;49(6 Pt 1):887-94.
2003: Ralf Lichtinghagen; Petra B Musholt; Carsten Stephan; Michael Lein; Glen Kristiansen; Steffen Hauptmann; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening; Klaus Jung
mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue.
Anticancer research 2003;23(3B):2617-24.
2003: Monika Jung; Andreas Römer; Gernot Keyszer; Michael Lein; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Klaus Jung
mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue.
The Prostate 2003;55(2):89-98.
2003: Klaus Jung; Hans-Willi Krell; Bernhard Ortel; Tayyaba Hasan; Andreas Römer; Dietmar Schnorr; Stefan A Loening; Michael Lein
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.
The Prostate 2003;54(3):206-11.
2002: Ralf Lichtinghagen; Petra B Musholt; Michael Lein; Andreas Römer; Birgit Rudolph; Glen Kristiansen; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue.
European urology 2002;42(4):398-406.
2002: Carsten Stephan; Henning Cammann; Axel Semjonow; Eleftherios P Diamandis; Leon F A Wymenga; Michael Lein; Pranav Sinha; Stefan A Loening; Klaus Jung
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies.
Clinical chemistry 2002;48(8):1279-87.
2002: Klaus Jung; Michael Lein; K v Hösslin; A Grosse; S Roth; K Possinger; D Lüftner
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults.
The International journal of biological markers 2002;17(3):177-81.
2002: D Mangoldt; B Sinn; Michael Lein; Hans-Willi Krell; Dietmar Schnorr; Stefan A Loening; Klaus Jung
The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells.
Apoptosis : an international journal on programmed cell death 2002;7(3):217-20.
2002: Carsten Stephan; Klaus Jung; Henning Cammann; Birgit Vogel; Brigitte Brux; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Michael Lein; Dietmar Schnorr; Pranav Sinha; Stefan A Loening
An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation.
International journal of cancer. Journal international du cancer 2002;99(3):466-73.
2002: Michael Lein; Klaus Jung; Bernhard Ortel; Carsten Stephan; Winfried Rothaug; Rolf Juchem; Manfred Johannsen; Serdar Deger; Dietmar Schnorr; Stefan A Loening; Hans-Willi Krell
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.
Oncogene 2002;21(13):2089-96.
2002: Carsten Stephan; Klaus Jung; Eleftherios P Diamandis; Harry G Rittenhouse; Michael Lein; Stefan A Loening
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Urology 2002;59(1):2-8.
2002: Ju Zhang; Klaus Jung; Michael Lein; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Ralf Lichtinghagen
Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines.
The Prostate 2002;50(1):38-45.
2001: Klaus Jung; Michael Lein; C Laube; Ralf Lichtinghagen
Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.
Clinica chimica acta; international journal of clinical chemistry 2001;314(1-2):241-4.
2001: Klaus Jung; Michael Lein; K von Hösslin; Brigitte Brux; Dietmar Schnorr; Stefan A Loening; Pranav Sinha
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer.
Clinical chemistry 2001;47(11):2061-3.
2001: Klaus Jung; Carsten Stephan; U Elgeti; Michael Lein; Brigitte Brux; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Pranav Sinha
Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
International journal of cancer. Journal international du cancer 2001;93(5):759-65.
2001: Michael Lein; Klaus Jung; Peter Hammerer; M Graefen; Axel Semjonow; P Stieber; M Ossendorf; Hans-Joachim Luboldt; Brigitte Brux; Carsten Stephan; Dietmar Schnorr; Stefan A Loening
A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
The Prostate 2001;47(2):77-84.
2001: Klaus Jung; Carsten Stephan; Michael Lein; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
The Prostate 2001;46(4):307-10.
2001: Michael Lein; Klaus Jung; U Elgeti; T Petras; Carsten Stephan; Brigitte Brux; Pranav Sinha; Björn Winkelmann; Dietmar Schnorr; Stefan A Loening
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
European urology 2001;39(1):57-64.
2000: Klaus Jung; Michael Lein; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(12):1271-5.
2000: Michael Lein; Klaus Jung; U Elgeti; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Anticancer research 2000;20(6D):4997-5001.
2000: Carsten Stephan; Klaus Jung; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(11):1133-47.
2000: Carsten Stephan; Klaus Jung; Brigitte Brux; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(4):309-11.
2000: Carsten Stephan; Klaus Jung; Brigitte Brux; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation.
Urology 2000;55(4):560-3.
2000: Michael Lein; Klaus Jung; C Laube; T Hübner; B Winkelmann; Carsten Stephan; Steffen Hauptmann; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
International journal of cancer. Journal international du cancer 2000;85(6):801-4.
2000: Klaus Jung; U Elgeti; Michael Lein; Brigitte Brux; Pranav Sinha; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Clinical chemistry 2000;46(1):55-62.
2000: Klaus Jung; Brigitte Brux; Michael Lein; Birgit Rudolph; Glen Kristiansen; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Pranav Sinha
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Clinical chemistry 2000;46(1):47-54.
1999: Michael Lein; Klaus Jung; Brigitte Brux; A Knäbich; P Sinha; Dietmar Schnorr; Stefan A Loening
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
The Journal of urology 1999;162(2):502-3.
1999: Michael Lein; L Nowak; Klaus Jung; C Laube; N Ulbricht; Dietmar Schnorr; Stefan A Loening
Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue.
Annals of the New York Academy of Sciences 1999;878():544-6.
1999: Michael Lein; Klaus Jung; L Nowak; Dietmar Schnorr; Stefan A Loening
Analytical aspects regarding the measurement of metalloproteinases.
Annals of the New York Academy of Sciences 1999;878():491-3.
1999: Klaus Jung; Brigitte Brux; Michael Lein; A Knäbich; Pranav Sinha; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Urology 1999;53(6):1160-7; discussion 1167-8.
1999: Klaus Jung; Brigitte Brux; A Knäbich; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia.
Clinical chemistry 1999;45(3):422-4.
1999: B Friedrich; Klaus Jung; Michael Lein; Ingolf Türk; Birgit Rudolph; G Hampel; Dietmar Schnorr; Stefan A Loening
Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.
European journal of cancer (Oxford, England : 1990) 1999;35(1):138-44.
1999: Klaus Jung; J Zachow; Michael Lein; Brigitte Brux; Pranav Sinha; Severin Lenk; Dietmar Schnorr; Stefan A Loening
Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared.
Urology 1999;53(1):155-60.
1998: Klaus Jung; C Laube; Michael Lein; Ingolf Türk; Ralf Lichtinghagen; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
International journal of cancer. Journal international du cancer 1998;78(3):392-3.
1998: Michael Lein; L Nowak; Klaus Jung; Frank Koenig; Dietmar Schnorr; Stefan A Loening
[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma].
Der Urologe. Ausg. A 1998;37(4):377-81.
1998: Klaus Jung; C Laube; Michael Lein; Ralf Lichtinghagen; H Tschesche; Dietmar Schnorr; Stefan A Loening
Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood.
Clinical chemistry 1998;44(5):1060-2.
1998: Klaus Jung; A Meyer; Michael Lein; B Rudolph; Dietmar Schnorr; Stefan A Loening
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
The Journal of urology 1998;159(5):1595-8.
1998: Klaus Jung; Michael Lein; N Ulbrich; Birgit Rudolph; W Henke; Dietmar Schnorr; Stefan A Loening
Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects.
The Prostate 1998;34(2):130-6.
1998: Michael Lein; C Stephan; Klaus Jung; Dietmar Schnorr; S Loening
Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
Cancer investigation 1998;16(1):45-9.
1997: A Meyer; Klaus Jung; Michael Lein; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Factors influencing the ratio of free to total prostate-specific antigen in serum.
International journal of cancer. Journal international du cancer 1997;74(6):630-6.
1997: Michael Lein; L Nowak; Klaus Jung; Frank Koenig; Ralf Lichtinghagen; Dietmar Schnorr; Stefan A Loening
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.
Clinical biochemistry 1997;30(6):491-6.
1997: Michael Lein; Brigitte Brux; Klaus Jung; W Henke; F Koenig; C Stephan; Dietmar Schnorr; Stefan A Loening
Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1997;35(8):591-5.
1997: Michael Lein; Klaus Jung; S Weiss; Dietmar Schnorr; S A Loening
Soluble CD44 variants in the serum of patients with urological malignancies.
Oncology 1997;54(3):226-30.
1997: Klaus Jung; L Nowak; Michael Lein; F Priem; Dietmar Schnorr; Stefan A Loening
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
International journal of cancer. Journal international du cancer 1997;74(2):220-3.
1997: C Stephan; Michael Lein; Klaus Jung; Dietmar Schnorr; Stefan A Loening
Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
The Journal of urology 1997;157(4):1371.
1997: W Henke; M Jung; Klaus Jung; Michael Lein; H Schlechte; C Berndt; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood.
International journal of cancer. Journal international du cancer 1997;70(1):52-6.
1997: Klaus Jung; B Seidel; Birgit Rudolph; Michael Lein; M V Cronauer; W Henke; G Hampel; Dietmar Schnorr; Stefan A Loening
Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells.
Free radical biology & medicine 1997;23(1):127-33.
1997: Carsten Stephan; Michael Lein; Klaus Jung; Dietmar Schnorr; Stefan A Loening
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Cancer 1997;79(1):104-9.
1996: Klaus Jung; L Nowak; Michael Lein; W Henke; Dietmar Schnorr; Stefan A Loening
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood.
Clinical chemistry 1996;42(12):2043-5.
1996: Klaus Jung; W Henke; Michael Lein; Dietmar Schnorr; S A Loening
Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
Cancer 1996;78(11):2445-8.
1996: Michael Lein; S Weiss; Klaus Jung; Dietmar Schnorr; S Loening
Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies.
The Prostate 1996;29(5):334-5.
1996: Klaus Jung; L Nowak; Michael Lein; W Henke; Dietmar Schnorr; Stefan A Loening
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?
Clinica chimica acta; international journal of clinical chemistry 1996;254(1):97-100.
1996: W Henke; M Jung; Klaus Jung; Michael Lein; Horst H Schlechte; C Berndt; B Rudolph; Dietmar Schnorr; Stefan A Loening
Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells.
Clinical chemistry 1996;42(9):1499-500.
1996: C Stephan; Klaus Jung; Michael Lein; Dietmar Schnorr; Stefan A Loening
The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume.
International journal of cancer. Journal international du cancer 1996;67(3):461-2.
1996: Klaus Jung; Michael Lein; W Henke; Dietmar Schnorr; S A Loening
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells?
The Prostate 1996;29(1):65-6.
1996: Klaus Jung; C Stephan; Michael Lein; W Henke; Dietmar Schnorr; Brigitte Brux; P Schürenkämper; Stefan A Loening
Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Clinical chemistry 1996;42(7):1026-33.
1996: Michael Lein; D Fahlenkamp; Bernd Schönberger; S Prollius; S Loening
The pharmacological effect of the gonadotrophin-releasing hormone on experimental cryptorchidism in rats.
Scandinavian journal of urology and nephrology 1996;30(3):185-91.
1996: Michael Lein; Klaus Jung; Dietmar Schnorr; W Henke; Stefan A Loening
Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1996;34(6):511-4.
1996: Klaus Jung; Michael Lein; Dietmar Schnorr; Brigitte Brux; W Henke; S Loening
Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?
Annals of clinical biochemistry 1996;33 ( Pt 3)():209-14.
1996: Klaus Jung; Michael Lein; S Weiss; Dietmar Schnorr; W Henke; S Loening
Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
European journal of cancer (Oxford, England : 1990) 1996;32A(4):627-30.
1996: D Fahlenkamp; M Beer; Bernd Schönberger; Michael Lein; Ingolf Türk; Stefan A Loening
Laparoscopic adrenalectomy.
Techniques in urology 1996;2(1):48-53.
1995: Michael Lein; Klaus Jung; Dietmar Schnorr; W Henke; Brigitte Brux; Stefan A Loening
Rapid screening of PSA: evaluation of an immunochemical membrane strip test.
Clinical chemistry 1995;41(10):1545-7.